Komori
Earnings4523Eisai Co.,Ltd.Pharmaceuticals

Preliminary revenue from sales of the anti-amyloid beta antibody Leqembi

Global sales revenue for the anti-amyloid beta antibody Leqembi in the first half of fiscal 2026 was ¥61.5 billion, exceeding the ¥41.1 billion recorded in the same period of the previous year. Sales were ¥32.5 billion in the United States, ¥13.0 billion in Japan and ¥9.7 billion in China.

Worth reading
62In focus
Scored from 1 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
204
¥100 million (year on year)
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026–30 September 2026
Net Sales615¥100 million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Regional sales¥325 100 million, ¥130 100 million, ¥97 100 million
Factors Behind Changes in Business Performance

The same period of the previous year included the impact of distributors building inventory in China in the first quarter.

Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Period Covered1 April 2026–30 September 2026
Net Sales¥615 100 million
Regional sales¥325 100 million, ¥130 100 million, ¥97 100 million
Factors Behind Changes in Business PerformanceThe same period of the previous year included the impact of distributors building inventory in China in the first quarter.
Items this document does not state (33)
Accounting standardsConsolidated / non-consolidatedOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The same period of the previous year included the impact of distributors building inventory in China in the first quarter.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Preliminary revenue from sales of the anti-amyloid beta antibody Leqembi | Eisai Co.,Ltd. (4523) timely disclosure | Komori